Argen X SE (ARGX) is a clinical-stage biotechnology company that focuses on the discovery and development of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company has a proprietary technology platform called NHance, which is designed to enhance the therapeutic properties of antibodies. Argen X is headquartered in Ghent, Belgium, and has operations in the United States. The company's lead product candidate is efgartigimod, a novel therapeutic antibody being developed for the treatment of several autoimmune diseases, including myasthenia gravis and immune thrombocytopenia. Argen X also has a pipeline of product candidates targeting other autoimmune diseases, as well as cancer.
Argen X SE (ARGX) is a clinical-stage biotechnology company that focuses on the discovery and development of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. The company has a proprietary technology platform called NHance, which is designed to enhance the therapeutic properties of antibodies. Argen X is headquartered in Ghent, Belgium, and has operations in the United States. The company's lead product candidate is efgartigimod, a novel therapeutic antibody being developed for the treatment of several autoimmune diseases, including myasthenia gravis and immune thrombocytopenia. Argen X also has a pipeline of product candidates targeting other autoimmune diseases, as well as cancer.